Recent Publications

MAX in cancer: dynamic role of MYC's partner-in-crime.
Steffeck AWT, Cordova AA, Abdulkadir SA.
Trends Cancer. 2026 Mar 2:S2405-8033(26)00001-4. doi: 10.1016/j.trecan.2026.01.001. Online ahead of print.
The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
Meeks JJ.
J Clin Invest. 2026 Mar 2;136(5):e202079. doi: 10.1172/JCI202079. eCollection 2026 Mar 2.
Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey-Holden Prostate Cancer Academy Meeting.
Stoyanova T, Priceman SJ, Ross AE, Tran PT, McKay RR, Pienta KJ, Soule HR, Miyahira AK.
Prostate. 2026 Mar;86(4):411-427. doi: 10.1002/pros.70102. Epub 2025 Dec 7.
Standardizing time-to-event reporting in single-arm BCG-unresponsive registration trials: a case for Kaplan-Meier.
Monda SM, Meeks JJ, Powles T, Morgan TM.
Ann Oncol. 2026 Mar;37(3):431-434. doi: 10.1016/j.annonc.2025.11.010. Epub 2025 Nov 24.
Factors Associated With Early Detection of Clinically Significant Prostate Cancer After a Negative Magnetic Resonance Imaging-Informed Biopsy.
Jang JW, Handa N, Alam R, Li Y, Kumar S, Slota J, Huang M, Schaeffer EM, Patel HD, Ross AE.
Urol Pract. 2026 Mar;13(2):156-165. doi: 10.1097/UPJ.0000000000000918. Epub 2025 Nov 11.
Harnessing Hitchhikers: Outer Membrane Vesicles Leading the Way in Advanced Cancer Therapeutics and Diagnostic- A Review.
Sharifzad F, et al. Among authors: thumbikat p.
Cancer Lett. 2026 Feb 26:218370. doi: 10.1016/j.canlet.2026.218370. Online ahead of print.
Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study.
Driscoll CB, et al. Among authors: schaeffer em, kundu sd.
World J Urol. 2026 Feb 26;44(1):202. doi: 10.1007/s00345-026-06309-0.
Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia.
Quan S, Unno K, Gupta DG, Yang W, Guo Q, Dufficy MF, Kerber MM, Elmashae AA, Pan H, Zhu JL, Schiltz GE, Abdulkadir SA.
J Med Chem. 2026 Feb 26;69(4):4439-4468. doi: 10.1021/acs.jmedchem.5c03128. Epub 2026 Feb 13.
Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.
Wang MM, Truica MI, Gattis BS, Oktawiec J, Sagar V, Basu AA, Bertin PA, Zhang X, Abdulkadir SA, Gianneschi NC.
Nat Commun. 2026 Feb 24;17(1):1706. doi: 10.1038/s41467-026-68913-3.
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
Gupta S, et al. Among authors: meeks jj.
Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.01.029. Online ahead of print.